PL2114395T3 - Kompozycje oftalmiczne i douszne płaszczyznowo amfifilowych polimerów i oligomerów oraz ich zastosowania - Google Patents

Kompozycje oftalmiczne i douszne płaszczyznowo amfifilowych polimerów i oligomerów oraz ich zastosowania

Info

Publication number
PL2114395T3
PL2114395T3 PL07870011T PL07870011T PL2114395T3 PL 2114395 T3 PL2114395 T3 PL 2114395T3 PL 07870011 T PL07870011 T PL 07870011T PL 07870011 T PL07870011 T PL 07870011T PL 2114395 T3 PL2114395 T3 PL 2114395T3
Authority
PL
Poland
Prior art keywords
ophthalmic
oligomers
amphiphilic polymers
otic compositions
facially amphiphilic
Prior art date
Application number
PL07870011T
Other languages
English (en)
Inventor
Richard W Scott
Original Assignee
Cellceutix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellceutix Corp filed Critical Cellceutix Corp
Publication of PL2114395T3 publication Critical patent/PL2114395T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0046Ear
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts or implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL07870011T 2006-12-29 2007-12-28 Kompozycje oftalmiczne i douszne płaszczyznowo amfifilowych polimerów i oligomerów oraz ich zastosowania PL2114395T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88280006P 2006-12-29 2006-12-29
EP07870011.9A EP2114395B1 (en) 2006-12-29 2007-12-28 Ophthalmic and otic compositions of facially amphiphilic polymers and oligomers and uses thereof
PCT/US2007/089001 WO2008083256A2 (en) 2006-12-29 2007-12-28 Ophthalmic and otic compositions of facially amphiphilic polymers and oligomers and uses thereof

Publications (1)

Publication Number Publication Date
PL2114395T3 true PL2114395T3 (pl) 2015-08-31

Family

ID=39589209

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07870011T PL2114395T3 (pl) 2006-12-29 2007-12-28 Kompozycje oftalmiczne i douszne płaszczyznowo amfifilowych polimerów i oligomerów oraz ich zastosowania

Country Status (12)

Country Link
US (5) US20090092574A1 (pl)
EP (1) EP2114395B1 (pl)
JP (2) JP5512279B2 (pl)
CN (3) CN101631543B (pl)
AU (1) AU2007339790B2 (pl)
CA (1) CA2674080C (pl)
DK (1) DK2114395T3 (pl)
ES (1) ES2538479T3 (pl)
HU (1) HUE025868T2 (pl)
PL (1) PL2114395T3 (pl)
PT (1) PT2114395E (pl)
WO (1) WO2008083256A2 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
RU2530899C2 (ru) * 2008-07-28 2014-10-20 Селлсьютикс Корпорейшн Противомалярийные соединения
TWI478915B (zh) * 2008-10-27 2015-04-01 Cellceutix Corp 宿主防禦之合成模擬物及其用途
ITTO20090131A1 (it) * 2009-02-24 2010-08-25 Liofarmaceutici Srl Composizioni oftalmiche contenenti teicoplanina
CA2804666A1 (en) * 2010-07-07 2012-01-12 Polymedix, Inc. Methods of immune modulation
US20120190653A1 (en) * 2011-01-20 2012-07-26 Dow Pharmaceutical Sciences, Inc. Therapeutic eye drop comprising doxycycline and a stabilizer
DK2709619T3 (en) 2011-05-16 2018-01-15 Cellceutix Corp RELATIONSHIPS FOR USING THE TREATMENT OF MUCOSITIS
TW202126313A (zh) * 2011-09-16 2021-07-16 美商遠景生物製藥股份有限公司 安定之普維酮—碘組成物
KR20140129030A (ko) * 2012-01-18 2014-11-06 셀슈틱스 코포레이션 캔디다증 및 아스퍼질러스 감염을 치료하기 위한 화합물 및 방법
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
JP6047203B2 (ja) * 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および/または治療のための宿主防御タンパク質(hdp)模倣薬
EA201890633A1 (ru) 2015-09-03 2018-09-28 Зе Администрейторс Оф Зе Тьюлейн Эдьюкейшнл Фанд Композиции и способы для многофункциональных растворов для дезинфекции и стерилизации
EP3478654A4 (en) * 2016-07-01 2020-02-26 Boulos&Cooper Pharmaceuticals PTY Ltd NEW ANTIBIOTICS
IT201900000561A1 (it) * 2019-01-14 2020-07-14 Medivis S R L Formulazioni topiche oftalmiche chimicamente e fisicamente stabili a base di Nepafenac
WO2021248008A1 (en) 2020-06-05 2021-12-09 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections
US12102622B2 (en) 2021-02-10 2024-10-01 Iolyx Therapeutics, Inc. Methods for ophthalmic delivery of roflumilast
WO2023049809A1 (en) 2021-09-22 2023-03-30 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3496179A (en) * 1967-10-11 1970-02-17 Pfizer & Co C 2-amino-3,4-dihydroquinazolines
SE352811B (pl) 1971-06-04 1973-01-15 Pharmacia Ab
US3960150A (en) 1971-09-09 1976-06-01 Alza Corporation Bioerodible ocular device
US3867519A (en) 1972-04-27 1975-02-18 Alza Corp Bioerodible drug delivery device
SE375007B (pl) 1972-11-30 1975-04-07 Pharmacia Ab
US3914402A (en) 1973-06-14 1975-10-21 Alza Corp Ophthalmic dosage form, for releasing medication over time
US3963025A (en) 1974-09-16 1976-06-15 Alza Corporation Ocular drug delivery device
US4186184A (en) 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4303637A (en) 1980-04-04 1981-12-01 Alza Corporation Medication indicated for ocular hypertension
US4559343A (en) 1982-09-07 1985-12-17 Alcon Laboratories, Inc. Nonirritating aqueous ophthalmic compositions comfort formulation for ocular therapeutic agents
US5223492A (en) 1987-10-27 1993-06-29 Nasraoui Nejib M Derivatives of 19-nor progesterone; process for producing them and the pharmaceutical compositions incorporating them
US5190927A (en) 1991-07-09 1993-03-02 Merck & Co., Inc. High-glyceryl, low-acetyl gellan gum for non-brittle gels
EP0629347B1 (en) * 1992-01-23 1997-07-02 Morinaga Milk Industry Co., Ltd. Antibacterial agent and treatment of article therewith
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
KR100439006B1 (ko) 1994-08-30 2005-04-06 파마시아 에이비 안과 치료용 장치,치료액체를 방출시키는 방법 및 액체 투여액용 패키지
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6025326A (en) 1995-07-07 2000-02-15 Intrabiotics Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of oral mucositis
US5994306A (en) 1995-11-22 1999-11-30 Intrabiotics Pharmaceuticals, Inc. Fine-tuned protegrins
JP3090125B2 (ja) * 1997-08-26 2000-09-18 千寿製薬株式会社 ソフトコンタクトレンズ用の眼科用組成物、ソフトコンタクトレンズの濡れ増強方法およびテルペノイドの吸着抑制方法
AU758563B2 (en) * 1998-08-20 2003-03-27 University Of North Carolina At Chapel Hill, The Dicationic dibenzofuran and dibenzothiophene compounds and methods of use thereof
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
JP2001261674A (ja) * 2000-03-22 2001-09-26 Mitsui Chemicals Inc ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬
FR2813080B1 (fr) * 2000-08-17 2002-11-29 Stago Diagnostica Peptides anti-heparine
US20060078626A1 (en) * 2000-11-08 2006-04-13 Bioconcept Laboratories Opthalmic and contact lens solutions with a peroxide source and a cationic polymeric preservative
US20030021761A1 (en) 2001-01-18 2003-01-30 Geltex Pharmaceuticals, Inc. Ionene polymers and their use in treating mucositis
ES2314087T3 (es) * 2001-03-08 2009-03-16 The Trustees Of The University Of Pennsylvania Polimeros facialmente anfifilicos como agentes antiinfecciosos.
AR034372A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
AU2002341566A1 (en) 2001-08-16 2003-04-01 Mucosal Therapeutics, Inc. Treatment and prevention of mucositis in cancer patients
EP1535235A1 (en) * 2002-05-28 2005-06-01 The Trustees of The University of Pennsylvania Methods, systems, and computer program products for computational analysis and design of amphiphilic polymers
JP2005529604A (ja) * 2002-06-13 2005-10-06 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 粗粒度モデルを用いる生体膜をシミュレートするための方法、システム、およびコンピュータプログラム製品
AU2003291087A1 (en) 2002-11-19 2004-06-15 Genzyme Corporation Ionene oligomers and polymers
WO2004082634A2 (en) * 2003-03-17 2004-09-30 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers and uses thereof
AU2003249114A1 (en) 2003-03-20 2004-10-11 Shiseido International France Cosmetic composition
US20040202687A1 (en) * 2003-04-14 2004-10-14 Babu M.K. Manoj Ciprofloxacin formulations and methods of making and using the same
US20050065091A1 (en) * 2003-09-18 2005-03-24 Gholam Peyman Stabilized ocular solutions
JP5260877B2 (ja) * 2004-01-23 2013-08-14 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 面に対して両親媒性のポリアリール及びポリアリールアルキニルのポリマー及びオリゴマー並びにそれらの使用
KR101172722B1 (ko) 2004-06-15 2012-08-16 폴리메딕스, 인코포레이티드 다가양이온성 화합물 및 이의 용도
AU2005332637B2 (en) * 2004-07-23 2011-04-07 The Trustees Of The University Of Pennsylvania Antimicrobial copolymers and uses thereof
CA2599205A1 (en) * 2005-02-25 2006-09-08 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer
ES2351665T3 (es) 2005-03-24 2011-02-09 Rottapharm S.P.A. Derivados de benzamidina para el tratamiento y la prevención de mucositis.
AU2006244080C1 (en) 2005-05-10 2012-02-02 The University Of Chicago Use of peptides derived from the growth factor AMP-18 for the treatment of mucositis
US7951829B2 (en) 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
JP2008137978A (ja) * 2006-12-05 2008-06-19 Canon Inc カルバゾール誘導体及びこれを用いた有機発光素子
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
US20100297257A1 (en) 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant
RU2530899C2 (ru) 2008-07-28 2014-10-20 Селлсьютикс Корпорейшн Противомалярийные соединения
TWI478915B (zh) * 2008-10-27 2015-04-01 Cellceutix Corp 宿主防禦之合成模擬物及其用途
EP2389067A4 (en) 2008-12-10 2012-06-13 Polymedix Inc ANTIMICROBIAL MOLECULES FOR THE TREATMENT OF MYCOBACTERIUM STRAINS WITH MULTIDRUG RESISTANCE AND LARGE RESISTANCE TO DRUGS
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
US20110178104A1 (en) * 2010-01-07 2011-07-21 Polymedix Inc. Anti-Heparin Compounds
TW201208677A (en) 2010-08-21 2012-03-01 Polymedix Inc Facially amphiphilic compounds, compositions, and uses thereof in treating cancer
DK2709619T3 (en) 2011-05-16 2018-01-15 Cellceutix Corp RELATIONSHIPS FOR USING THE TREATMENT OF MUCOSITIS
KR20140129030A (ko) 2012-01-18 2014-11-06 셀슈틱스 코포레이션 캔디다증 및 아스퍼질러스 감염을 치료하기 위한 화합물 및 방법
WO2014093231A2 (en) 2012-12-10 2014-06-19 Cellceutix Corporation Hybrid compounds and methods of making and using the same
WO2014093225A2 (en) 2012-12-10 2014-06-19 Cellceutix Corporation Polycyclic compounds and methods of making and using the same
US9993469B2 (en) 2013-05-28 2018-06-12 Morphochem Aktiengesellschaft Für Kombinatorishe Chemie Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections
JP6047203B2 (ja) 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および/または治療のための宿主防御タンパク質(hdp)模倣薬

Also Published As

Publication number Publication date
JP2010514798A (ja) 2010-05-06
EP2114395A2 (en) 2009-11-11
JP2014139219A (ja) 2014-07-31
WO2008083256A3 (en) 2008-12-24
DK2114395T3 (en) 2015-06-08
EP2114395B1 (en) 2015-03-04
EP2114395A4 (en) 2010-12-15
CN101631543A (zh) 2010-01-20
US20190314370A1 (en) 2019-10-17
WO2008083256A2 (en) 2008-07-10
JP5745666B2 (ja) 2015-07-08
CN102600163B (zh) 2014-10-01
AU2007339790A1 (en) 2008-07-10
CN102600163A (zh) 2012-07-25
US20160228435A1 (en) 2016-08-11
CA2674080C (en) 2016-08-09
US9192623B2 (en) 2015-11-24
CN102342941A (zh) 2012-02-08
JP5512279B2 (ja) 2014-06-04
US20210093636A1 (en) 2021-04-01
US20090092574A1 (en) 2009-04-09
US20130065818A1 (en) 2013-03-14
AU2007339790B2 (en) 2013-07-18
CN101631543B (zh) 2011-12-07
HUE025868T2 (en) 2016-05-30
ES2538479T3 (es) 2015-06-22
US10166232B2 (en) 2019-01-01
CA2674080A1 (en) 2008-07-10
PT2114395E (pt) 2015-07-07

Similar Documents

Publication Publication Date Title
PT2114395E (pt) Composições oftálmicas e auriculares de polímeros e oligómeros facialmente anfifílicos e as suas utilizações
ZA200901386B (en) Masterbatch and polymer composition
GB0911139D0 (en) Directly photodefinable polymer compositions and methods thereof
HUE038560T2 (hu) Polimerek és készítményeik molekulatömeg-eloszlásának szabályzására vonatkozó eljárások
IL252421B (en) Preparations containing solid dispersions and their uses
EP2128196A4 (en) POLYMERIC COMPOSITION AND APPLICATION THEREOF
DK2139466T3 (en) Magnesium Compositions and Uses Thereof
ZA201008169B (en) Compositions and methods comprising variant microbial proteases
PL2134351T3 (pl) Sposoby i kompozycje do przedłużonego uwalniania chromu
AU2007291030A8 (en) Novel compositions and methods
IL179296A0 (en) Amphiphilic polymer compositions and their use
GB0622399D0 (en) Novel compositions and uses thereof
EP2231781A4 (en) HARDENING COMPOSITION AND HARDENING PRODUCT MADE THEREFOR
EP2207819B8 (en) Anti-microbial polymers and their compositions
GB0715428D0 (en) Compositions and uses thereof
ZA201103500B (en) New polymers and use thereof in preparation of high impact polymeric compositions
GB0701170D0 (en) Compositions and uses thereof
EP2010141A4 (en) NUCLEOTIDE COMPOSITIONS HAVING HIGH DEPOSITS AND USES THEREOF
GB0701171D0 (en) Compositions and uses thereof
PL2128112T3 (pl) Cząsteczkowe kompozycje odpowietrzające i sposoby ich stosowania
GB0622400D0 (en) Novel compositions and uses thereof
GB0725264D0 (en) Compositions and uses thereof
GB0718825D0 (en) Salaris and tulearins and compositions and uses thereof
AU2008903576A0 (en) Anti-Microbial Polymers and Their Compositions
AU2007903935A0 (en) Prophylactic and therapeutic compositions